House Bill Seeks to Add Mandatory Drug Recall Authority to FDA’s Arsenal
By Zachary Brennan -
Published 16 February 2017
Rep. Rosa DeLauro (D-CT) on Thursday introduced a new bill that will allow the US Food and Drug Administration (FDA) to do what many assume it already can: Require pharmaceutical or over-the-counter drug companies to stop marketing unsafe products.
Categories: US, FDA, Drugs, Product withdrawl and retirement, Regulatory intelligence, Regulatory strategy
Tags: DeLauro, mandatory drug recall, FDA authority, drug recalls, homeopathic
Asia Regulatory Roundup: India Begins Reviewing Drug Recall Guidelines (29 November 2016)
By Nick Paul Taylor -
Published 29 November 2016
Welcome to our Asia Regulatory Roundup, our weekly overview of the top regulatory news in Asia.
Categories: News, Asia, CDSCO, CFDA, TGA, Biologics and biotechnology, Drugs, Government affairs, Manufacturing, Medical Devices, Regulatory intelligence, Regulatory strategy
Tags: drug recalls, medicinal cannabis, antidiabetic
Number of Drug Recalls Surges at FDA, Led by Mid-Level Concerns
By Alexander Gaffney, RAC -
Published 11 August 2014
Recalls of pharmaceutical products have surged in recent years, and 2014 is already shaping up to be the biggest year for serious drug recalls in the last decade, according to data made publicly available by the US Food and Drug Administration (FDA) late last month.
Categories: News, US, CDER, Drugs, Postmarket surveillance, Product withdrawl and retirement
Tags: Recall, Drug Recalls, FDA Recalls, Drug Recalls Increasing, Class I Recall, Class II Recall, Class II Recall